2017 Q1 Form 10-K Financial Statement

#000156459017003722 Filed on March 08, 2017

View on sec.gov

Income Statement

Concept 2017 Q1 2016 Q4 2015 Q4
Revenue $270.0K $70.00K $110.0K
YoY Change 145.45% -36.36% -13.39%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.380M $2.180M $3.030M
YoY Change -0.83% -28.05% 180.56%
% of Gross Profit
Research & Development $2.061M $3.110M $1.770M
YoY Change -9.84% 75.71% 26.43%
% of Gross Profit
Depreciation & Amortization $48.00K $100.0K $100.0K
YoY Change -54.29% 0.0% -75.0%
% of Gross Profit
Operating Expenses $4.442M $5.290M $4.794M
YoY Change -5.11% 10.35% 94.09%
Operating Profit -$4.171M -$4.683M
YoY Change -8.77% 160.46%
Interest Expense $17.00K $40.00K -$450.0K
YoY Change -98.27% -108.89% -190.0%
% of Operating Profit
Other Income/Expense, Net $16.00K
YoY Change -20.0%
Pretax Income -$4.140M -$3.750M -$5.130M
YoY Change 15.32% -26.9% 294.62%
Income Tax
% Of Pretax Income
Net Earnings -$4.138M -$3.750M -$5.129M
YoY Change 15.2% -26.89% 293.93%
Net Earnings / Revenue -1532.59% -5357.14% -4662.73%
Basic Earnings Per Share
Diluted Earnings Per Share -$4.549M -$4.688M -$6.662M
COMMON SHARES
Basic Shares Outstanding 1.000M 12.03M 11.43M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2017 Q1 2016 Q4 2015 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $14.50M $17.10M $32.50M
YoY Change -47.65% -47.38% 2066.67%
Cash & Equivalents $14.53M $10.26M $29.10M
Short-Term Investments $0.00 $6.800M $3.400M
Other Short-Term Assets $13.70M $20.50M $35.70M
YoY Change -58.1% -42.58% 8825.0%
Inventory
Prepaid Expenses
Receivables $200.0K $0.00 $500.0K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $28.54M $37.52M $68.70M
YoY Change -53.02% -45.38% 3218.74%
LONG-TERM ASSETS
Property, Plant & Equipment $399.0K $444.0K $698.0K
YoY Change -41.5% -36.39% -23.38%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $100.0K $100.0K $100.0K
YoY Change 0.0% 0.0% 733.33%
Total Long-Term Assets $524.0K $569.0K $823.0K
YoY Change -35.07% -30.86% -9.66%
TOTAL ASSETS
Total Short-Term Assets $28.54M $37.52M $68.70M
Total Long-Term Assets $524.0K $569.0K $823.0K
Total Assets $29.06M $38.09M $69.52M
YoY Change -52.78% -45.21% 2232.14%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $899.0K $837.0K $939.0K
YoY Change 25.38% -10.86% 277.11%
Accrued Expenses $1.400M $1.400M $1.500M
YoY Change 40.0% -6.67% -40.22%
Deferred Revenue
YoY Change
Short-Term Debt $12.70M $19.40M $33.70M
YoY Change -58.9% -42.43%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $15.22M $21.97M $37.76M
YoY Change -54.32% -41.82% 1516.27%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $0.00 $100.0K $300.0K
YoY Change -100.0% -66.67% -72.73%
Total Long-Term Liabilities $0.00 $100.0K $300.0K
YoY Change -100.0% -66.67% -72.73%
TOTAL LIABILITIES
Total Short-Term Liabilities $15.22M $21.97M $37.76M
Total Long-Term Liabilities $0.00 $100.0K $300.0K
Total Liabilities $15.22M $22.02M $38.10M
YoY Change -54.63% -42.2% 1002.31%
SHAREHOLDERS EQUITY
Retained Earnings -$152.1M -$148.0M -$131.0M
YoY Change 12.99% 12.93% 12.7%
Common Stock $2.000K $1.000K $1.000K
YoY Change -81.82% 0.0% -97.06%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $13.84M $16.07M $31.43M
YoY Change
Total Liabilities & Shareholders Equity $29.06M $38.09M $69.52M
YoY Change -52.78% -45.21% 2232.14%

Cashflow Statement

Concept 2017 Q1 2016 Q4 2015 Q4
OPERATING ACTIVITIES
Net Income -$4.138M -$3.750M -$5.129M
YoY Change 15.2% -26.89% 293.93%
Depreciation, Depletion And Amortization $48.00K $100.0K $100.0K
YoY Change -54.29% 0.0% -75.0%
Cash From Operating Activities -$4.300M -$5.000M -$5.100M
YoY Change -8.51% -1.96% -120.4%
INVESTING ACTIVITIES
Capital Expenditures $3.000K -$200.0K -$100.0K
YoY Change -96.63% 100.0%
Acquisitions
YoY Change
Other Investing Activities $6.800M $6.000M $11.00M
YoY Change -283.78% -45.45% -156.41%
Cash From Investing Activities $6.800M $5.800M $11.00M
YoY Change -278.95% -47.27% -156.41%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $1.782M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -5.000M 0.000 200.0K
YoY Change -100.0% -89.47%
NET CHANGE
Cash From Operating Activities -4.300M -5.000M -5.100M
Cash From Investing Activities 6.800M 5.800M 11.00M
Cash From Financing Activities -5.000M 0.000 200.0K
Net Change In Cash -2.464M 800.0K 6.100M
YoY Change -71.01% -86.89% -17.57%
FREE CASH FLOW
Cash From Operating Activities -$4.300M -$5.000M -$5.100M
Capital Expenditures $3.000K -$200.0K -$100.0K
Free Cash Flow -$4.303M -$4.800M -$5.000M
YoY Change -10.15% -4.0% -120.0%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2016Q4 us-gaap Stockholders Equity
StockholdersEquity
16071000
CY2016Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
38090000
CY2016Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
7000
CY2016Q4 us-gaap Liabilities
Liabilities
22019000
CY2016Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-147982000
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
10264000
CY2016Q4 us-gaap Short Term Investments
ShortTermInvestments
6800000
CY2016Q4 us-gaap Accounts Receivable Gross Current
AccountsReceivableGrossCurrent
31000
CY2015Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
66248000
CY2015Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2015Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2016Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2016Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2015Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2015Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
762005
CY2015Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
762005
CY2015 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
326000
CY2016Q4 us-gaap Assets Current
AssetsCurrent
37521000
CY2016Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
444000
CY2016Q4 us-gaap Assets
Assets
38090000
CY2016Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
837000
CY2016Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
596000
CY2016Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
805000
CY2015 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
272000
CY2015 us-gaap Operating Income Loss
OperatingIncomeLoss
-13802000
CY2015 us-gaap Operating Expenses
OperatingExpenses
15552000
CY2016 us-gaap Operating Income Loss
OperatingIncomeLoss
-20418000
CY2016 us-gaap Operating Expenses
OperatingExpenses
20817000
CY2015Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
33794000
CY2015Q4 us-gaap Deposits Assets Current
DepositsAssetsCurrent
133000
CY2015Q4 us-gaap Accounts Receivable Gross Current
AccountsReceivableGrossCurrent
492000
CY2015 cbio Interest And Other Income Expense Net
InterestAndOtherIncomeExpenseNet
518000
CY2016 cbio Interest And Other Income Expense Net
InterestAndOtherIncomeExpenseNet
3473000
CY2015 us-gaap Net Income Loss
NetIncomeLoss
-14762000
CY2016 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2016 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2016 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2016 dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
CY2017Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
1000036
CY2016Q2 dei Entity Public Float
EntityPublicFloat
12081112
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
29096000
CY2015Q4 us-gaap Short Term Investments
ShortTermInvestments
3402000
CY2016Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
19468000
CY2016Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
958000
CY2015Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1781000
CY2015Q4 us-gaap Assets Current
AssetsCurrent
68698000
CY2016Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
125000
CY2015Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
125000
CY2015Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
698000
CY2015Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
66247000
CY2015Q4 us-gaap Assets
Assets
69521000
CY2015Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
939000
CY2015Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
926000
CY2015Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
535000
CY2016Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
283000
CY2015Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
438000
CY2016Q4 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
41000
CY2015Q4 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
19000
CY2016Q4 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
19403000
CY2015Q4 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
33743000
CY2015Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
1156000
CY2016Q4 us-gaap Liabilities Current
LiabilitiesCurrent
21965000
CY2015Q4 us-gaap Liabilities Current
LiabilitiesCurrent
37756000
CY2016Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
47000
CY2015Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
292000
CY2015Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
48000
CY2015Q4 us-gaap Liabilities
Liabilities
38096000
CY2016Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2015Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2016Q4 us-gaap Common Stock Value
CommonStockValue
1000
CY2015Q4 us-gaap Common Stock Value
CommonStockValue
1000
CY2016Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
164053000
CY2015Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
162460000
CY2016Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-1000
CY2015Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
1000
CY2015Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-131037000
CY2015Q4 us-gaap Stockholders Equity
StockholdersEquity
31425000
CY2015Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
69521000
CY2015Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2015Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2016Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2016Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2016Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2016Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
801756
CY2016Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
801756
CY2016 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9262000
CY2015 us-gaap Interest Expense
InterestExpense
1478000
CY2016 us-gaap Net Income Loss
NetIncomeLoss
-16945000
CY2016 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-21.75
CY2015 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-49.99
CY2016 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
779166
CY2015 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
295272
CY2016 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-2000
CY2015 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
1000
CY2015 us-gaap Proceeds From Issuance Of Convertible Preferred Stock
ProceedsFromIssuanceOfConvertiblePreferredStock
7259000
CY2016 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-16947000
CY2015 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-14761000
CY2014Q4 us-gaap Stockholders Equity
StockholdersEquity
-109352000
CY2015 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
326000
CY2015 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
13000
CY2015 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
117647000
CY2015 us-gaap Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt
AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt
774000
CY2015 us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
36537000
CY2016 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
635000
CY2016 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
957000
CY2016 us-gaap Share Based Compensation
ShareBasedCompensation
635000
CY2015 us-gaap Share Based Compensation
ShareBasedCompensation
326000
CY2016 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
389000
CY2015 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
470000
CY2015 us-gaap Paid In Kind Interest
PaidInKindInterest
1478000
CY2016 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
557000
CY2015 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-15000
CY2016 us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
1674000
CY2016 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
99000
CY2015 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
52000
CY2015 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-91000
CY2016 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
1057000
CY2015 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
242000
CY2016 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-461000
CY2015 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
79000
CY2016 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-956000
CY2016 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-102000
CY2016 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-60000
CY2016 us-gaap Increase Decrease In Prepaid Rent
IncreaseDecreaseInPrepaidRent
19000
CY2015 us-gaap Increase Decrease In Prepaid Rent
IncreaseDecreaseInPrepaidRent
-41000
CY2016 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-400000
CY2015 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-1749000
CY2016 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-18472000
CY2015 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-19118000
CY2015 cbio Proceeds From Reverse Merger
ProceedsFromReverseMerger
23931000
CY2016 us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
10002000
CY2015 us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
13823000
CY2016 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
13401000
CY2016 us-gaap Proceeds From Sale Of Productive Assets
ProceedsFromSaleOfProductiveAssets
1674000
CY2016 us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
5000
CY2015 us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
125000
CY2016 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
890000
CY2016 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
468000
CY2016 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-1308000
CY2015 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
37357000
CY2016 us-gaap Proceeds From Repayments Of Restricted Cash Financing Activities
ProceedsFromRepaymentsOfRestrictedCashFinancingActivities
14330000
CY2015 us-gaap Proceeds From Repayments Of Restricted Cash Financing Activities
ProceedsFromRepaymentsOfRestrictedCashFinancingActivities
3255000
CY2016 us-gaap Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
14340000
CY2015 us-gaap Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
3020000
CY2016 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
958000
CY2015 us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
1888000
CY2015 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
82000
CY2015 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
13000
CY2016 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
948000
CY2015 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
9313000
CY2016 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-18832000
CY2015 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
27552000
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1544000
CY2015 cbio Investment Securities Received From Reverse Merger
InvestmentSecuritiesReceivedFromReverseMerger
17223000
CY2015 cbio Redeemable Convertible Notes Assumed Upon Reverse Merger
RedeemableConvertibleNotesAssumedUponReverseMerger
37073000
CY2016 cbio Noncash Or Part Noncash Unrealized Gain Loss On Investments
NoncashOrPartNoncashUnrealizedGainLossOnInvestments
-2000
CY2015 cbio Noncash Or Part Noncash Unrealized Gain Loss On Investments
NoncashOrPartNoncashUnrealizedGainLossOnInvestments
1000
CY2015 cbio Embedded Derivative Related To Redeemable Convertible Notes
EmbeddedDerivativeRelatedToRedeemableConvertibleNotes
1455000
CY2016 us-gaap Nature Of Operations
NatureOfOperations
<div> <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:5.24%;white-space:nowrap"> <p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1.</font></p></td> <td valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Nature of Operations</p></td></tr></table></div> <p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Catalyst Biosciences, Inc. (the &#8220;Company&#8221; or &#8220;Catalyst&#8221;), is a clinical-stage biotechnology company focused on developing novel medicines to address hematology indications, including the treatment of hemophilia. Its facilities are in South San Francisco, California and it operates in one segment.</p> <p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On February 10, 2017, the Company effected a reverse stock split of its common stock at a ratio of 1-for-15 (&#8220;2017 Reverse Stock Split&#8221;). The 2017 Reverse Stock Split was approved by the Company&#8217;s stockholders at a special meeting of stockholders held on February 2, 2017. As a result of the 2017 Reverse Stock Split, each 15 pre-split shares of common stock outstanding were automatically combined into one new share of common stock, and the number of outstanding shares of common stock on the date of the split was reduced from approximately 13.0 million shares to approximately 868,000 shares. Unless otherwise specified, all share and per share amounts in these notes and the accompanying consolidated financial statements are reported on a post-stock split basis for all periods presented.</p> <p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Reverse Merger</p> <p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prior to August 20, 2015, the name of the Company was Targacept, Inc. On August 20, 2015, Targacept completed its business combination with Catalyst Bio, Inc. (&#8220;Catalyst Bio&#8221;) in accordance with the terms of an Agreement and Plan of Merger, dated as of March 5, 2015, as amended on May 6 and May 13, 2015, by and among Targacept, Talos Merger Sub, Inc. (&#8220;Merger Sub&#8221;) and Catalyst Bio, pursuant to which Merger Sub merged with and into Catalyst Bio, with Catalyst Bio surviving as a wholly-owned subsidiary of Targacept (the &#8220;Merger&#8221;). Also on August 20, 2015, in connection with, and prior to the completion of, the Merger, Targacept effected a 1-for-7 reverse stock split of its common stock (the &#8220;Reverse Stock Split&#8221;) and changed its name from Targacept, Inc. to Catalyst Biosciences, Inc. Following the completion of the Merger, the business conducted by the Company became primarily the business conducted by Catalyst Bio described in the paragraph above. We refer in this Annual Report on Form 10-K to the business combination as the &#8220;Merger,&#8221; to the Company prior to the Merger as &#8220;Targacept&#8221; and to our subsidiary as &#8220;Catalyst Bio,&#8221; and discussions of historical results reflect the results of Catalyst Bio prior to the completion of the Merger and do not include the historical results of Targacept prior to the completion of the Merger. </p> <p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On August 19, 2015, prior to and in connection with the Merger, the Company paid a dividend to the Targacept holders consisting of cash and non-interest bearing redeemable convertible notes (the &#8220;Pre-Closing Dividend&#8221;), see <font style="font-style:italic;">Note 9</font> for further detail. In connection with the Pre-Closing Dividend and the reverse-stock split, the Company adjusted the number of shares subject to each outstanding option to purchase its common stock. On August 20, 2015, upon the completion of the Merger, the Company issued shares of its common stock to Catalyst Bio stockholders in exchange for each share of Catalyst Bio common stock outstanding immediately prior to the Merger and assumed all the outstanding options and warrants of Catalyst Bio, with such options and warrants henceforth representing the right to purchase a number of shares of the Company&#8217;s common stock. All preferred stock and warrants were converted to common stock and warrants to purchase common stock upon the closing of the Merger. </p> <p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Liquidity</p> <p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We had a net loss of $16.9 million for the year ended December 31, 2016 and an accumulated deficit of $148.0 million as of December 31, 2016 and expect to continue to incur losses for the next several years. As of December 31, 2016, we had $17.1 million in cash, cash equivalents and short-term investments, a $16.9 million net loss and $18.5 million cash used in operations. Management believes that the currently available resources, including cash, cash equivalents and short term investments as well as the cash raised from the sale of common stock in January 2017 (see Note 14) and availability under our Capital on Demand Sales Agreement (See Note 14), will provide sufficient funds to enable us to meet its operating plan for at least the next twelve months from the date of this filing. </p> <p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">However, if our anticipated operating results are not achieved in future periods, management believes that planned expenditures can be reduced to extend the time period over which the then-available resources would be able to fund our operations. We plan to continue to fund losses from operations and capital funding needs through future equity and/or debt financings, as well as potential additional asset sales, licensing transactions, collaborations or strategic partnerships with other companies. The sale of additional equity or convertible debt could result in additional dilution to our stockholders. The incurrence of indebtedness would result in debt service obligations and could result in operating and financing covenants that would restrict our operations. We can provide no assurance that financing will be available in the amounts we need or on terms acceptable to us, if at all. If we are not able to secure adequate additional funding we may be forced to delay, make reductions in spending, extend payment terms with suppliers, liquidate assets where possible, and/or suspend or curtail planned programs. Any of these actions could materially harm our business.</p></div>
CY2015 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
700000
CY2016 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. On an ongoing basis, management evaluates its estimates, including those related to revenue recognition, convertible notes and related warrants up to the date of conversion, common stock and stock-based compensation. The Company bases its estimates on various assumptions that the Company believes to be reasonable under the circumstances. Actual results could differ from those estimates.</p></div>
CY2016Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
1137000
CY2015Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
1285000
CY2016Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
745000
CY2015 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
0
CY2016 cbio Operating Lease Expiration Date
OperatingLeaseExpirationDate
2018-02
CY2016 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
700000
CY2016Q4 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
17100000
CY2016 cbio Reduction To Research And Development Expense
ReductionToResearchAndDevelopmentExpense
100000
CY2015 cbio Reduction To Research And Development Expense
ReductionToResearchAndDevelopmentExpense
900000
CY2015Q4 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
1156000
CY2015Q4 us-gaap Fair Value Net Derivative Asset Liability Measured On Recurring Basis With Unobservable Inputs
FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs
1156000
CY2016 us-gaap Fair Value Net Derivative Asset Liability Measured On Recurring Basis Change In Unrealized Gain Loss
FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss
-1057000
CY2016 us-gaap Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Gain Loss Included In Earnings
FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings
-99000
CY2016Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
36551000
CY2016Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
2000
CY2016Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
36549000
CY2015Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
2000
CY2015Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
1000
CY2015Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
66248000
CY2016 us-gaap Available For Sale Securities Gross Realized Gain Loss Net
AvailableForSaleSecuritiesGrossRealizedGainLossNet
0
CY2016Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
2304000
CY2015Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
6399000
CY2016Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1860000
CY2015Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
5701000
CY2016 us-gaap Depreciation
Depreciation
400000
CY2015 us-gaap Depreciation
Depreciation
500000
CY2016 us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
600000
CY2015 us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
0
CY2016Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
125000
CY2016Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
870000
CY2013 cbio License Fees Payable
LicenseFeesPayable
100000
CY2016 us-gaap Interest Expense Related Party
InterestExpenseRelatedParty
0
CY2015 us-gaap Interest Expense Related Party
InterestExpenseRelatedParty
1500000
CY2016 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
635000
CY2015 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.3400
CY2016Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
25944000
CY2015Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
17650000
CY2016Q4 cbio Deferred Tax Assets Fixed Assets And Intangibles
DeferredTaxAssetsFixedAssetsAndIntangibles
114000
CY2016 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P7Y1M2D
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
15524910
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
16683
CY2015 cbio Share Based Compensation Arrangement By Share Based Payment Award Options Assumed In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInPeriod
94721
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
45039
CY2015 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
254
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
2436
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
7119
CY2016 cbio Aggregate Fractional Shares Written Off Upon Conversion Of Options Assumed In Merger
AggregateFractionalSharesWrittenOffUponConversionOfOptionsAssumedInMerger
4
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
6573
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
140990
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
106472
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
68977
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
85849
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
134.40
CY2015 cbio Sharebased Compensation Arrangements By Sharebased Payment Award Options Assumed In Merger Weighted Average Exercise Price
SharebasedCompensationArrangementsBySharebasedPaymentAwardOptionsAssumedInMergerWeightedAverageExercisePrice
227.40
CY2015 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
44.70
CY2015 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
50.70
CY2015 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
127.20
CY2015 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
708.00
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
147.45
CY2016 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
23.70
CY2016 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
259.05
CY2016 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
64.95
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
128.25
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
152.70
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
74.70
CY2014 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P5Y6M4D
CY2015 cbio Share Based Compensation Arrangement By Share Based Payment Award Options Assumed In Merger Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInMergerWeightedAverageRemainingContractualTerm
P4Y4D
CY2015 cbio Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 Granted
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2Granted
P9Y9M22D
CY2015 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P5Y6M4D
CY2016 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P3Y11M5D
CY2016 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P2Y3M11D
CY2015 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.0133
CY2015 cbio Effective Income Tax Rate Reconciliation Permanent Differences
EffectiveIncomeTaxRateReconciliationPermanentDifferences
-0.0800
CY2015 us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
-0.1159
CY2015 cbio Effective Income Tax Rate Reconciliation Derecognition
EffectiveIncomeTaxRateReconciliationDerecognition
-2.4087
CY2015 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
2.0417
CY2016 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Other
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
0.0043
CY2016Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
3174000
CY2015Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
2625000
CY2015Q4 cbio Deferred Tax Assets Fixed Assets And Intangibles
DeferredTaxAssetsFixedAssetsAndIntangibles
95000
CY2016Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
30369000
CY2015Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
21655000
CY2016 cbio Research And Development Tax Credit Carry Forwards Derecognized
ResearchAndDevelopmentTaxCreditCarryForwardsDerecognized
5600000
CY2016Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
1539000
CY2015Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
1314000
CY2014Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
2570000
CY2015 us-gaap Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
1347000
CY2015 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
91000
CY2016 us-gaap Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
-6000
CY2016 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
219000
CY2016Q4 us-gaap Income Tax Examination Penalties And Interest Accrued
IncomeTaxExaminationPenaltiesAndInterestAccrued
0
CY2015Q4 us-gaap Income Tax Examination Penalties And Interest Accrued
IncomeTaxExaminationPenaltiesAndInterestAccrued
0
CY2016 cbio Change In Derivative Liability
ChangeInDerivativeLiability
1156000
CY2015 cbio Change In Derivative Liability
ChangeInDerivativeLiability
387000
CY2016 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
86000
CY2015 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
131000
CY2016 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
293796
CY2015 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
403572

Files In Submission

Name View Source Status
0001564590-17-003722-index-headers.html Edgar Link pending
0001564590-17-003722-index.html Edgar Link pending
0001564590-17-003722.txt Edgar Link pending
0001564590-17-003722-xbrl.zip Edgar Link pending
cbio-10k_20161231.htm Edgar Link pending
cbio-20161231.xml Edgar Link completed
cbio-20161231.xsd Edgar Link pending
cbio-20161231_cal.xml Edgar Link unprocessable
cbio-20161231_def.xml Edgar Link unprocessable
cbio-20161231_lab.xml Edgar Link unprocessable
cbio-20161231_pre.xml Edgar Link unprocessable
cbio-ex1014_551.htm Edgar Link pending
cbio-ex1016_464.htm Edgar Link pending
cbio-ex231_468.htm Edgar Link pending
cbio-ex311_458.htm Edgar Link pending
cbio-ex312_459.htm Edgar Link pending
cbio-ex321_457.htm Edgar Link pending
cbio-ex322_456.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
g2017030821290326028361.jpg Edgar Link pending
g2017030821290327028362.jpg Edgar Link pending
g2017030821290328628363.jpg Edgar Link pending
g2017030821290329828364.jpg Edgar Link pending
g2017030821290330728365.jpg Edgar Link pending
g2017030821290331828366.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending